<DOC>
	<DOCNO>NCT00727311</DOCNO>
	<brief_summary>The objective study assess safety efficacy PegIntron injector Rebetol administer participant chronic hepatitis C. Participants treat general practitioner clinical practice part post-marketing surveillance study . The study ass rate eradication hepatits C virus rate serious adverse event report PegIntron ( 1.5 μg/kg/week ) Rebetol ( 800-1200 mg/day ) common medical practice Germany .</brief_summary>
	<brief_title>Real-life Surveillance Study Patients With Chronic Hepatitis C Treated With PegIntron Injector Rebetol ( Study P04538 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants chronic hepatitis C At least 18 year old Treatmentnaïve relapse interferon monotherapy Platelets &gt; = 100,000/mm^3 Neutrophil count &gt; = 1,500/ mm^3 Thyroid Stimulating Hormone ( TSH ) must within normal limit Hemoglobin &gt; = 12 gr/dl ( female ) ; &gt; = 13 gr/dl ( male ) Intravenous drug abuser ( ExIVDA ) participant stable substitution least 6 month Women childbearing potential must routine pregnancy test perform monthly treatment 7 month thereafter . Sexually active female participant childbearing potential must practice adequate contraception ( intrauterine device , oral contraceptive , implanted contraceptive , surgical sterilization , barrier method , monogamous relationship male partner vasectomy use condom ( + spermicide ) treatment period 7 month stop treatment Sexually active male participant must practice acceptable method contraception ( vasectomy , use condom + spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 7 month stop treatment Contraindications per SPC approve European labeling Hypersensitivity active substance inteferons excipients Pregnant woman Woman breastfeed Existence history severe psychiatric condition , particular severe depression , suicidal ideation suicide attempt A history severe preexist cardiac disease , include unstable uncontrolled cardiac disease previous six month Severe debilitate medical condition , include participant chronic renal failure creatinine clearance &lt; 50 mL/min Autoimmune hepatitis history autoimmune disease Severe hepatic dysfunction decompensated cirrhosis liver Preexisting thyroid disease unless control conventional therapy Epilepsy and/or compromise central nervous system function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>